Tim Sauer

10PUBLICATIONS
109CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsEpidemiological modellingGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Sep 17, 2026
IDH3 regulates citrate homeostasis to control metabolic fitness and venetoclax resistance of AML stem cells.

|Aug 19, 2025
International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML.

Swati Naik, Richard Aplenc, Susanne H C Baumeister

|Jul 30, 2025
TIGIT Affects CAR NK-cell Effector Function in the Solid Tumor Microenvironment by Modulating Immune Synapse Strength.

Ishwar Navin, Matthew Dysthe, Prashant S Menon

|Nov 06, 2024
Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia.

Leo Ruhnke, Marius Bill, Sven Zukunft

|Sep 18, 2024
Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML.

Julia M Unglaub, Richard F Schlenk, Jan Moritz Middeke

|Sep 16, 2024
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.

Christoph Röllig, Björn Steffen, Christoph Schliemann

Pageof 2

Frequent Collaborators

6 joint publications

Carsten Müller-Tidow

5 joint publications

Christoph Röllig

4 joint publications

Martin Bornhäuser

3 joint publications

Stefan W Krause